Mangalam Drugs & Organics
Healthcare
Mangalam Drugs and Organics Ltd
MANGALAM NSE
₹29.73 +0.55 (+1.88%)
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹29.73 −34.08 −53.4% 1Y
Start ₹63.81
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- −13.80%
- Debt to Equity
- 1.10
- EPS (TTM)
- −₹23.78
- Book Value
- ₹60.64
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 0.49
- ROE
- −34.80%
- Dividend Yield
- 0.00%
- EBITDA
- −₹14.10 Cr
- 52W High
- ₹66.19
- 52W Low
- ₹22.80
- Day Range
- ₹28.61 – ₹30.40
- Volume
- 19,371
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Mangalam Drugs & Organics (this company) | ₹29.73 | — | ₹47 Cr | 0.49 | 0.00% | −34.80% | −13.80% | ₹232 Cr | −₹38 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
37 Weak
Data confidence 91/100
surveillance:ASM1
Category scores
- Quality
- 43
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 45
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 14
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 12
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 51
- Average
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.49 times its book value
Weaknesses
6- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.39% over past five years.
- Promoter holding is low: 35.6%
- Company has a low return on equity of -11.0% over last 3 years.
- Debtor days have increased from 45.3 to 63.4 days.
- Promoter holding has decreased over last 3 years: -14.7%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 9 | 7 | 3 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bearish | 7 | 0 | 3 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Bearish
Bearish
9
Neutral
7
Bullish
3
Moving Averages
Strong Bearish
Bearish
7
Neutral
0
Bullish
3
Key readings
- RSI (14)
- 47.65
- Neutral
- MACD (12,26,9)
- −0.56
- Bearish
- SMA (50)
- 31.09
- Bearish
- SMA (200)
- 30.83
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | −2.37% |
|---|---|
| 5Y | −9.40% |
| 3Y | −14.56% |
| 1Y | −27.04% |
| TTM | −22.20% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Turned to loss |
| 3Y | Turned to loss |
| 1Y | Turned to loss |
| TTM | Loss widened by ₹28.15 Cr |
Operating cash flow
| 10Y | −15.67% |
|---|---|
| 5Y | −32.24% |
| 3Y | −52.78% |
| 1Y | −90.70% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −19.35 pp |
|---|---|
| 5Y | −20.42 pp |
| 3Y | −13.46 pp |
| 1Y | −17.79 pp |
| TTM | −11.42 pp |
Revenue by year
| Mar 2017 | ₹299 Cr |
|---|---|
| Mar 2018 | ₹269 Cr |
| Mar 2019 | ₹228 Cr |
| Mar 2020 | ₹282 Cr |
| Mar 2021 | ₹380 Cr |
| Mar 2022 | ₹451 Cr |
| Mar 2023 | ₹372 Cr |
| Mar 2024 | ₹369 Cr |
| Mar 2025 | ₹318 Cr |
| Mar 2026 | ₹232 Cr |
Net profit by year
| Mar 2017 | ₹22.00 Cr |
|---|---|
| Mar 2018 | ₹20.00 Cr |
| Mar 2019 | −₹8.00 Cr |
| Mar 2020 | ₹8.00 Cr |
| Mar 2021 | ₹28.00 Cr |
| Mar 2022 | ₹20.00 Cr |
| Mar 2023 | ₹1.00 Cr |
| Mar 2024 | −₹9.00 Cr |
| Mar 2025 | ₹7.00 Cr |
| Mar 2026 | −₹44.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 87.47 | 81.56 | 97.34 | 102 | 76.54 | 79.94 | 88.71 | 72.78 | 57.21 | 49.54 | 58.38 | 67.29 | 57.12 |
| Expenses | 90.94 | 79.37 | 90.36 | 90.54 | 68.34 | 71.25 | 79.94 | 62.88 | 61.86 | 52.37 | 59.96 | 72.65 | 56.22 |
| Operating Profit | −3.48 | 2.19 | 6.98 | 11.7 | 8.19 | 8.69 | 8.77 | 9.9 | −4.65 | −2.83 | −1.58 | −5.36 | 0.9 |
| OPM % | −3.98% | 2.69% | 7.17% | 11.44% | 10.7% | 10.87% | 9.89% | 13.6% | −8.13% | −5.71% | −2.71% | −7.97% | 1.58% |
| Other Income | 0.02 | 0.03 | 0 | 0.05 | 0.02 | 0.14 | 0.13 | 0.47 | 0.14 | 0.03 | 0.22 | 0.09 | 0.11 |
| Interest | 3.41 | 3.24 | 3.31 | 3.95 | 3.75 | 3.67 | 3.49 | 4.03 | 4.04 | 5.03 | 4.05 | 3.08 | 3.68 |
| Depreciation | 3.42 | 3.73 | 3.62 | 3.86 | 3.87 | 3.97 | 3.93 | 4.61 | 4.38 | 4.53 | 4.37 | 4.56 | 3.99 |
| PBT | −10.29 | −4.75 | 0.05 | 3.94 | 0.59 | 1.2 | 1.48 | 1.73 | −12.93 | −12.37 | −9.78 | −12.91 | −6.66 |
| Tax % | −7.29% | −25.05% | −920% | 9.9% | −355.93% | −125.21% | 5.41% | 90.75% | 6.19% | −41.42% | 0% | 1.16% | 13.36% |
| Net Profit | −9.54 | −3.56 | 0.5 | 3.55 | 2.68 | 2.69 | 1.4 | 0.15 | −13.73 | −7.25 | −9.78 | −13.06 | −7.55 |
| EPS (₹) | −6.03 | −2.25 | 0.32 | 2.24 | 1.69 | 1.7 | 0.88 | 0.09 | −8.67 | −4.58 | −6.18 | −8.25 | −4.77 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 232 | 232 |
| Expenses | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 247 | 241 |
| Operating Profit | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | −15 | −9 |
| OPM % | 9% | 13% | 16% | 17% | 4.3% | 8% | 14% | 11% | 7% | 4.7% | 11% | −6% | −3.8% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0.15 | 1 | 0 |
| Interest | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 16 | 16 |
| Depreciation | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 18 | 17 |
| PBT | 6 | 24 | 31 | 29 | −6 | 6 | 40 | 28 | 2 | −11 | 5 | −48 | −42 |
| Tax % | −2% | 33% | 29% | 32% | 40% | −32% | 29% | 29% | 43% | −18% | −39% | −9% | — |
| Net Profit | 6 | 16 | 22 | 20 | −8 | 8 | 28 | 20 | 1 | −9 | 7 | −44 | −38 |
| EPS (₹) | 4.66 | 11.15 | 14.08 | 12.57 | −5.07 | 5.21 | 17.67 | 12.42 | 0.8 | −5.72 | 4.37 | −27.68 | −23.78 |
| Div. Payout % | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 | 87 |
| Borrowings | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 | 113 |
| Other Liabilities | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 | 92 |
| Total Liabilities | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 308 |
| Fixed Assets | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 | 148 |
| CWIP | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 | 4 |
| Investments | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 | 156 |
| Total Assets | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 308 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 14 | 22 | 43 | 25 | 22 | 31 | 28 | 26 | 38 | 12 | 43 | 4 |
| Investing | −4 | −11 | −39 | −16 | −9 | −7 | −31 | −27 | −22 | −18 | −19 | −12 |
| Financing | −10 | −11 | −3 | −9 | −11 | −23 | 3 | 3 | −17 | 6 | −22 | 6 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 1 | 0 | −1 | 1 | −1 | 0 | 2 | −2 |
| Free Cash Flow | 10 | 11 | 3 | 9 | 12 | 24 | −4 | −2 | 16 | −6 | 23 | −8 |
| CFO/OP | 69 | 68 | 107 | 66 | 223 | 129 | 69 | 70 | 148 | 71 | 121 | −30 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 | 63 |
| Inventory Days | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 | 239 |
| Days Payable | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 | 160 |
| Cash Conversion Cycle | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 | 142 |
| Working Capital Days | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 | −54 |
| ROCE % | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% | −14% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Mangalam Drugs & Organics insights
67 extracted metrics across FY05–FY27.
Documents
- 13 Nov 2025
- 24 Nov 2025
- 19 Nov 2025
- 7 Nov 2025
- 15 Jan 2025
- 21 Nov 2023
- Defaults under para a sub-paragraph 6 of schedule 16 Oct 2026
Frequently Asked Questions about Mangalam Drugs & Organics
What does Mangalam Drugs and Organics Ltd do?
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.
Where is Mangalam Drugs and Organics Ltd (MANGALAM) listed?
Mangalam Drugs and Organics Ltd trades as MANGALAM on the NSE and under code 532637 on the BSE.
Which sector does Mangalam Drugs and Organics Ltd belong to?
Mangalam Drugs and Organics Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Mangalam Drugs and Organics Ltd?
Over the last 52 weeks Mangalam Drugs and Organics Ltd has traded between ₹22.8 and ₹66.19 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd reported a return on equity of -34.80%. Its debt-to-equity ratio is 1.10.
Company Information
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MANGALAM.md for Mangalam Drugs and Organics Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.